About: Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
Creator	Chu, Yanhui Wang, Quanyi Li, Jing Wang, Xiaoli Pan, Yang Feng, Yingmei Guo, Xianghua Prof, Asso Xin, Qianqian Youan, Beijing
source	MedRxiv
abstract	Background. COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging. Methods. A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. The presence of neutralizing antibody was determined with a modified cytopathogenic assay based on live SARS-CoV-2. The dynamics of neutralizing antibody levels at different with different clinical characteristics were analyzed. Results. The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till day 41-53. The total GMT was 1:163.7 (95% CI, 128.5 to 208.6), and the antibody level was highest during day 31-40 since onset, and then decreased slightly. Individual differences in changes of antibody levels were observed among 8 representative convalescent patients. In multivariate GEE analysis, patients at age of 31-60 and 61-84 had a higher antibody level than those at age of 16-30 (β=1.0518, P=0.0152; β=1.3718, P=0.0020). Patients with a worse clinical classification had a higher antibody titer (β=0.4639, P=0.0227). Conclusions. The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients. Moreover, changes on antibody levels ware individual specific.
has issue date	2020-04-18(xsd:dateTime)
bibo:doi	10.1101/2020.04.15.20065623
has license	medrxiv
sha1sum (hex)	5f9db5381c15cb1cd77d11eef019e14829da5b92
schema:url	https://doi.org/10.1101/2020.04.15.20065623
resource representing a document's title	Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
resource representing a document's body	covid:5f9db5381c15cb1cd77d11eef019e14829da5b92#body_text
is schema:about of	named entity 'neutralizing antibodies' named entity 'SARS-CoV-2' named entity 'Neutralizing Antibodies' named entity 'Hubei' named entity 'peer review' named entity 'therapeutic agents' named entity 'IgG' named entity 'assay' named entity 'antibody' named entity 'Chi-square test' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'antibody' named entity 'GMT' named entity 'peer review' named entity 'antibody' named entity 'titer' named entity '1:64' named entity 'neutralizing antibody' named entity 'peer review' named entity 'medRxiv' named entity 'Serum samples' named entity 'seropositivity' named entity 'medRxiv' named entity 'virus' named entity 'Chi-square test' named entity 'GMT' named entity 'viruses' named entity 'peer review' named entity 'white blood cell count' named entity 'immunogenicity' named entity 'antibody' named entity 'SARS-CoV' named entity 'coronaviruses' named entity 'virus' named entity 'Coronaviridae' named entity 'GMT' named entity 'antibodies' named entity 'incubation' named entity 'coronavirus' named entity 'China' named entity 'medRxiv' named entity 'viral infection' named entity 'GMT' named entity 'seropositivity' named entity 'peer review' named entity 'Wuhan' named entity 'data analysis' named entity 'GMT' named entity 'titer' named entity 'antibody' named entity 'neutralizing antibody' named entity 'vaccines' named entity 'serum' named entity 'asymptomatic' named entity 'medRxiv' named entity 'medRxiv' named entity '36.5°C' named entity 'COVID' named entity 'seropositivity' named entity 'COVID' named entity 'Vero cells' named entity 'medRxiv' named entity 'peer review' named entity 'antibodies' named entity '1:64' named entity 'COVID' named entity 'titer' named entity 'titer' named entity 'titer' named entity 'IgG' named entity 'medRxiv' named entity 'hypertension' named entity 'positive-sense RNA' named entity 'neutralizing antibody' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software